Record overview
Status and phase
Status: COMPLETED
Phase: PHASE2
Sponsor: Eisai Inc.
Condition: Locally Recurrent, Metastatic Breast Cancer ( HER2 Negative)
NCT01268150
A Study of Single-Agent Eribulin Mesylate as First-Line Therapy for Locally Recurrent or Metastatic Human Epidermal Growth Factor Receptor Two (HER2) Negative Breast Cancer
Public trial-level signal summary for this oncology Phase 2 record.
Signal summary
Public flags
Status signal: Low Signal
Timeline signals: stale_update_signal
Results signal: Low Signal
Operational burden: rare_population_signal
Stopped reason
Context when available
No stop reason available in the current public record.